PA5-95477

antibody from Invitrogen Antibodies

Targeting: TREM1 CD354, TREM-1

Western blot (Supportive data in Antibodypedia)

Immunohistochemistry (Recommended by provider)

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-95477

Provider

Invitrogen Antibodies

Product name

TREM1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Recombinant full-length protein

Description

Reconstitute with 0.2 mL of distilled water to yield a concentration of 500 µg/mL.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µg

Concentration

500 µg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Identification of Immune-Related Genes Contributing to the Development of Glioblastoma Using Weighted Gene Co-expression Network Analysis.

Kong Y, Feng ZC, Zhang YL, Liu XF, Ma Y, Zhao ZM, Huang B, Chen AJ, Zhang D, Thorsen F, Wang J, Yang N, Li XG
Frontiers in immunology 2020;11:1281

Western blot

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Western blot analysis of TREM1 in Lane 1: recombinant human TREM1 protein (1 ng). Electrophoresis was performed with 5-20% SDS-PAGE gel (70V, Stacking gel; 90V Resolving gel, Time: 2-3 hours), transferred to a nitrocellulose membrane and blocked using 5% Non-fat Milk/TBS (1.5 hrs at room temperature). Samples were incubated with TREM1 polyclonal antibody (Product # PA5-95477) using a 0.5 µg/mL dilution, followed by a goat anti-rabbit IgG-HRP at a dilution of 1:10,000, and developed with enhanced chemiluminescence (ECL).

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow cytometry of TREM1 in H-PBMC cells (blue line), isotype control rabbit IgG (green line) and unlabeled (red line). Samples were blocked with 10% goat serum, incubated with TREM1 polyclonal antibody (Product # PA5-95477) at a dilution of 1 µg (per 1x10^6 cells), followed by 488 conjugated goat anti-rabbit IgG (30 min at 20°C) using a 5-10 µg (per 1x10^6 cells) dilution.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Flow Cytometry of TREM1 in human PBMC cells (blue line), isotype control rabbit IgG (green line) and unlabeled (red line). Samples were blocked with 10% goat serum, incubated with TREM1 Polyclonal Antibody (Product # PA5-95477) at a dilution of 1 μg (per 1x10^6 cells), followed by DyLight®488 conjugated goat anti-rabbit IgG (for 30 minutes at 20°C) using 5-10 μg (per 1x10^6 cells) dilution.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

NULL

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 6 Inhibition of TREM1 suppresses migration and vasculary mimicry formation of GBM cells in vitro . (A) RT-qPCR results for TREM1, CD206 , and CD163 in macrophages derived from the THP1 cell line under normoxia and hypoxia. (B) Western blot analysis of TREM1 protein levels under normoxia and hypoxia. (C) Graphical representation of qRT-PCR after siRNA knockdown of TREM1. ACTB was used as an internal reference. (D) Western blot to validate the efficiency of si-TREM1 knockdown in macrophages derived from the THP1 cell line. ACTB was used as a protein loading control. (E) Representative images of Transwell migration for U87MG and LN229 under normoxia, hypoxia plus control, and hypoxia plus si-TREM1 (scale bar: 200 mum). Statistical results of the invasive ratio with corresponding treatment for 24 h in the Transwell assay. (F) Representative images of VM formation assay for U87MG in normoxia, hypoxia plus control, and hypoxia plus si-TREM1. (G) RT-qPCR to detect mRNA expression of TGF- alpha, CSF1, CSF2 , and VEGFA after knockdown of TREM1 under hypoxia. (H) Statistical results of the invasive ratio for U87MG and LN229 in both control and pexidartinib (10 muM) treatment under hypoxia. (I) Representative images of VM formation assay for U87MG in both control and pexidartinib (10 muM) groups under hypoxic conditions. Significant difference between the two groups: * P < 0.05; ** P < 0.01; *** P < 0.001.